Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis.

Li M, Yang Y, Jiang D, Ying M, Wang Y, Zhao R

Medicine1 Sept 2017Cited by 19 (Europe PMC)

PMID28953663PMCIDPMC5626306DOI10.1097/md.0000000000008161PepBankPUB-28953663

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes on metformin, liraglutide 1.2 mg and 1.8 mg lowered HbA1c more than sitagliptin (mean difference -0.35).
In plain wordsIn adults with type 2 diabetes on metformin, liraglutide lowered HbA1c more than sitagliptin did.
Peptide
Liraglutide
Outcome
DecreaseHbA1c versus sitagliptin
Study
n: not reported in source
Comparator
Sitagliptin plus metformin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg and 1.8 mgAs given in this study (human).
Source sentences
Summary
Compared with sitagliptin combination with metformin group, participants' treatment with 1.2 mg and 1.8 mg liraglutide with metformin could significantly lower the level of glycosylated hemoglobin (HbA1c) (P < .00001, MD = -0.35, 95% CI -0.51 to -0.20).
1 context sentence(design, population, supporting numbers)
Summary · context
Only randomized controlled trials (RCTs) of liraglutide versus sitagliptin both in combination with metformin up to 31 August 2016 were included.
Report a problemFND-2895366301
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes on metformin, liraglutide 1.8 mg gave significantly more weight loss than sitagliptin (mean difference -1.12).
In plain wordsIn adults with type 2 diabetes on metformin, liraglutide 1.8 mg led to more weight loss than sitagliptin.
Peptide
Liraglutide
Outcome
DecreaseBody weight versus sitagliptin
Study
n: not reported in source
Comparator
Sitagliptin plus metformin
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mgAs given in this study (human).
Source sentences
Summary
Moreover, patients with 1.8 mg liraglutide group had significant body weight loss (P < .00001, MD = -1.12, 95% CI -1.54 to -0.70).
1 context sentence(design, population, supporting numbers)
Summary · context
Only randomized controlled trials (RCTs) of liraglutide versus sitagliptin both in combination with metformin up to 31 August 2016 were included.
Report a problemFND-2895366302
03HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes on metformin, systolic blood pressure did not differ between liraglutide and sitagliptin.
In plain wordsIn adults with type 2 diabetes on metformin, systolic blood pressure was not clearly different between liraglutide and sitagliptin.
Peptide
Liraglutide
Outcome
No significant changeSystolic blood pressure versus sitagliptin
Study
n: not reported in source
Comparator
Sitagliptin plus metformin
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
However, there were no obvious differences in cutting down the systolic blood pressure and diastolic blood pressure between liraglutide-metformin and sitagliptin-metformin groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Only randomized controlled trials (RCTs) of liraglutide versus sitagliptin both in combination with metformin up to 31 August 2016 were included.
Report a problemFND-2895366303
04HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes on metformin, diastolic blood pressure did not differ between liraglutide and sitagliptin.
In plain wordsIn adults with type 2 diabetes on metformin, diastolic blood pressure was not clearly different between liraglutide and sitagliptin.
Peptide
Liraglutide
Outcome
No significant changeDiastolic blood pressure versus sitagliptin
Study
n: not reported in source
Comparator
Sitagliptin plus metformin
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
However, there were no obvious differences in cutting down the systolic blood pressure and diastolic blood pressure between liraglutide-metformin and sitagliptin-metformin groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Only randomized controlled trials (RCTs) of liraglutide versus sitagliptin both in combination with metformin up to 31 August 2016 were included.
Report a problemFND-2895366304
05HumanSystematic reviewSafety outcome
In adults with type 2 diabetes on metformin, gastrointestinal problems were significantly more frequent with liraglutide than with sitagliptin.
In plain wordsIn adults with type 2 diabetes on metformin, stomach and gut side effects were more common with liraglutide than with sitagliptin.
Peptide
Liraglutide
Outcome
IncreaseGastrointestinal adverse events versus sitagliptin
Study
n: not reported in source
Comparator
Sitagliptin plus metformin
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
The incidence of gastrointestinal problems was significantly higher than sitagliptin with metformin groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Only randomized controlled trials (RCTs) of liraglutide versus sitagliptin both in combination with metformin up to 31 August 2016 were included.
Report a problemFND-2895366305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.